Andrew Satz: Expediting the U.S. Drug Approval Process
Audio is streamed directly from the publisher (buzzsprout.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
How do we expedite the drug approval process in the United States? Co-Founder & CEO of EVQLV, Andrew Satz, educates us on how and what is needed to do so.
To find out more about Andrew, please find him on LinkedIn here: https://www.linkedin.com/in/andrewsatz/
To find out more about EVQLV, please find the company website here: https://evqlv.com/
Key takeaways:
1. The acceleration of getting drugs to patients by decreasing costs for researchers, industry, and other key stakeholders motivates EVQLV.
2. A.I. will cause hyper-specialization, which will make doctors become more productive.
3. Making data more accessible through government agencies and investing at a governmental level will drive future A.I. models and specialized medicines for populations.